Abstract:Abstract Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel therapeutic class for treating anemia in patients with chronic kidney disease. Small molecule analogs of α-ketoglutarate (AKG), an essential substrate for 2-oxoglutarate-dependent dioxygenases (2-OGDDs), including prolyl hydroxylase domain proteins (PHDs), inhibit PHD pharmacologically and thereby prevent HIF degradation. HIF stabilization alleviates anemia through several stimulatory effects on erythropoiesis, but it also affects the expression of many anemia-unrelated genes whose protein products exert important functions in vivo. Therefore, the pleiotropic effects of HIF stabilization under normoxic conditions deserve to be examined in more detail. Specifically, we believe that particular attention should be given to epigenetic modifications among the various AKG-based metabolic systems that may be altered by HIF-PHIs. It is noteworthy that AKG has been reported to exert health-protective actions. AKG-based metabolic systems include enzymes associated with the tricarboxylic acid cycle and amino acid metabolism, as well as 2-OGDD-mediated processes, which play important roles in many biological reactions. In this review, we examine the multifaceted effects of HIF-PHIs, encompassing not only their on-target effect of HIF stabilization but also their off-target inhibitory effects on various AKG-based metabolic systems. Furthermore, we examine its potential relevance to cardiovascular complications, based on clinical and animal studies suggesting its involvement in vascular calcification, thrombogenesis, and heart failure. In conclusion, although HIF-PHIs offer a promising avenue for anemia treatment in CKD patients, their broader impact on multiple biological systems raises substantial concerns. The intricate interplay between HIF stabilization, AKG competition, and cardiovascular complications warrants extensive, long-term investigations to ensure the safety and usefulness of HIF-PHIs in clinical practice.

A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)

Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016-2020)

Recent Progress of Prolyl Hydroxylase Domain Inhibitors

HIF-1: structure, biology and natural modulators

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia

The Regulatory Mechanism of Hypoxia-inducible Factor 1 and its Clinical Significance

Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1

Action Sites and Clinical Application of HIF-1α Inhibitors

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective

FDA approves first hypoxia-inducible factor prolyl hydroxylase inhibitor

[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors]

Hypoxia signaling in human diseases and therapeutic targets

The role of hypoxia-inducible factors in metabolic diseases

HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

Growing Concerns About Using Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia

Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach

The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy

Regulation of iron metabolism by hypoxia-inducible factors.

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer